Hospital
Carilion Tazewell Community Hospital
Carilion Tazewell Community Hospital was paid $8.03M by Medicaid between Jan 2018 and Dec 2024, across 121 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoCARILION TAZEWELL COMMUNITY HOSPITAL
TAZEWELL, VA 24651
TAZEWELL, VA 24651
33aNPI1427040328assigned 08/17/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.03M
24GClaims236,955
24DCodes billed121
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#55 of 80
Median peer was paid$14.69M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official PRESCOTT, ELEANOR controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 32,057 | $659K | |
| 2019 | 36,752 | $979K | |
| 2020 | 29,121 | $965K | |
| 2021 | 36,238 | $1.06M | |
| 2022 | 37,853 | $1.31M | |
| 2023 | 39,040 | $1.55M | |
| 2024incomplete | 25,894 | $1.51M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 10,362 | 9,179 | $1.56M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 9,000 | 7,946 | $1.37M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 6,085 | 5,181 | $990K |
| 96361 | Intravenous infusion, hydration; each additional hour | 11% | 3,660 | 3,249 | $858K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.7% | 3,455 | 2,605 | $458K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.7% | 3,422 | 3,071 | $457K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.3% | 2,352 | 1,739 | $427K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.4% | 6,381 | 1,688 | $355K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.3% | 4,573 | 4,185 | $265K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.6% | 1,437 | 1,087 | $206K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 2,432 | 2,071 | $169K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.7% | 589 | 519 | $135K |
109 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 2,165 | $84K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,477 | $78K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 474 | $63K |
| 80053 | Comprehensive metabolic panel | <1% | 14,722 | $62K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,091 | $51K |
| 97161 | <1% | 349 | $46K | |
| 71045 | Radiologic examination, chest; single view | <1% | 8,672 | $38K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,104 | $30K |
| 83880 | <1% | 2,767 | $26K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 202 | $25K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,852 | $24K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,368 | $18K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 15,560 | $18K |
| 87040 | <1% | 2,247 | $15K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 359 | $13K |
| 84484 | <1% | 6,295 | $13K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 784 | $12K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 249 | $12K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 63 | $9K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,145 | $9K |
| 97014 | <1% | 279 | $8K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,131 | $8K |
| 83735 | <1% | 8,525 | $8K | |
| 85379 | <1% | 1,474 | $7K | |
| 81001 | <1% | 5,217 | $6K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,291 | $5K |
| 83605 | <1% | 3,439 | $5K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 846 | $5K |
| 99220 | <1% | 138 | $5K | |
| 73564 | <1% | 354 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,985 | $4K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,902 | $4K |
| 73630 | <1% | 303 | $4K | |
| 85610 | <1% | 5,835 | $3K | |
| 72100 | <1% | 182 | $3K | |
| 36600 | <1% | 1,117 | $3K | |
| J3490 | Unclassified drugs | <1% | 4,033 | $3K |
| 85730 | <1% | 4,702 | $3K | |
| 73030 | <1% | 239 | $3K | |
| 80179 | <1% | 572 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,384 | $3K |
| 72131 | <1% | 45 | $2K | |
| 87081 | <1% | 3,417 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,028 | $2K |
| 82150 | <1% | 1,744 | $2K | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 278 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,451 | $2K |
| 81025 | <1% | 930 | $2K | |
| 80143 | <1% | 590 | $2K | |
| 73130 | <1% | 101 | $1K | |
| 73610 | <1% | 225 | $1K | |
| 81003 | <1% | 2,318 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,109 | $1K |
| 82962 | <1% | 1,797 | $1K | |
| 96376 | <1% | 1,223 | $1K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 553 | $1K |
| 82803 | <1% | 767 | $1K | |
| 84703 | <1% | 1,640 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 50 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,003 | $1K |
| 93971 | <1% | 33 | $1K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 7,882 | $834.50 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,878 | $650.97 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,328 | $633.76 |
| 87186 | <1% | 870 | $616.54 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 500 | $526.50 |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 14 | $484.74 |
| 87807 | <1% | 61 | $477.67 | |
| 90715 | <1% | 27 | $474.90 | |
| 80306 | <1% | 350 | $443.93 | |
| 71250 | <1% | 13 | $364.25 | |
| 87077 | <1% | 668 | $299.29 | |
| 82140 | <1% | 187 | $237.59 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 732 | $184.06 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 34 | $178.98 |
| 85652 | <1% | 190 | $132.24 | |
| 73110 | <1% | 20 | $130.10 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 189 | $125.60 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 255 | $96.19 |
| 85027 | <1% | 19 | $53.48 | |
| 83690 | <1% | 807 | $47.40 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 313 | $25.96 |
| Q0169 | Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 17 | $18.73 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 208 | $16.88 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 131 | $16.14 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 34 | $16.10 |
| 87147 | <1% | 26 | $9.44 | |
| 82550 | <1% | 16 | $5.06 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 76 | $4.85 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 56 | $4.63 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 87 | $2.20 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 16 | $1.69 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 14 | $1.40 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 18 | $1.36 |
| J1815 | Injection, insulin, per 5 units | <1% | 19 | $0.33 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 132 | $0.00 |
| 87205 | 0% | 12 | $0.00 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 45 | $0.00 |
| 87070 | 0% | 12 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 13 | $0.00 |
| J3535 | Drug administered through a metered dose inhaler | 0% | 14 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 12 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 14 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 2,552 | $0.00 |
| S0077 | Injection, clindamycin phosphate, 300 mg | 0% | 14 | $0.00 |
| S0164 | Injection, pantoprazole sodium, 40 mg | 0% | 65 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 14 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 45 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPRESCOTT, ELEANOR (GOVERNMENT PROGRAM MANAGER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.